| Year |
Citation |
Score |
| 2021 |
Kong A, Mehanna H. WEE1 Inhibitor: Clinical Development. Current Oncology Reports. 23: 107. PMID 34269904 DOI: 10.1007/s11912-021-01098-8 |
0.35 |
|
| 2019 |
Mumin NH, Drobnitzky N, Patel A, Lourenco LM, Cahill FF, Jiang Y, Kong A, Ryan AJ. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. Bmc Cancer. 19: 102. PMID 30678647 DOI: 10.1186/s12885-019-5295-z |
0.586 |
|
| 2018 |
Garcia Foncillas J, Aftimos PG, Barthelemy P, Bellmunt J, Berchem G, Camps C, de Las Peñas R, Finzel A, Hervonen JP, Joensuu T, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, et al. Clinical utility of complex multi-platform profiling in metastatic cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii480. PMID 32137238 DOI: 10.1093/Annonc/Mdy294.004 |
0.348 |
|
| 2017 |
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168: 357-364. PMID 29198055 DOI: 10.1007/s10549-017-4596-7 |
0.497 |
|
| 2016 |
Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. Plos Biology. 14: e1002414. PMID 26949965 DOI: 10.1371/journal.pbio.1002414 |
0.697 |
|
| 2015 |
Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Medical Press). 7: 147-62. PMID 26089701 DOI: 10.2147/BCTT.S54414 |
0.768 |
|
| 2015 |
Leung WY, Roxanis I, Sheldon H, Buffa FM, Li JL, Harris AL, Kong A. Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget. 6: 5678-94. PMID 25691057 |
0.824 |
|
| 2015 |
Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets and Therapy. 7: 147-162. DOI: 10.2147/BCTT.S54414 |
0.768 |
|
| 2014 |
Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5: 5934-49. PMID 25153719 |
0.839 |
|
| 2014 |
Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, ... ... Kong A, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5: 6633-46. PMID 24952873 |
0.675 |
|
| 2014 |
Im S, Juric D, Baselga J, Kong A, Martin P, Lin C, Dees EC, Schellens JHM, De Braud FG, Delgado L, Zucchetto M, Tian X, Fernandez R, Morozov A, Dirix LY. A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer. Journal of Clinical Oncology. 32: 2519-2519. DOI: 10.1200/Jco.2014.32.15_Suppl.2519 |
0.434 |
|
| 2014 |
Albukhari A, Choudhry H, Haider S, Buffa F, Ahmed A, Kong A. 529: Identification of novel determinants of cetuximab-resistance in triple negative breast cancer European Journal of Cancer. 50: S128. DOI: 10.1016/S0959-8049(14)50471-6 |
0.776 |
|
| 2013 |
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, ... ... Kong A, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research : Bcr. 15: R92. PMID 24286369 DOI: 10.1186/Bcr3493 |
0.507 |
|
| 2013 |
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, ... ... Kong A, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 4: 1592-605. PMID 24009064 DOI: 10.18632/Oncotarget.1148 |
0.804 |
|
| 2013 |
Awada A, Rodriguez AA, Kong A, Erban JK, Cortes J, Mano MS, Perez EA, El Hariry I, Vukovic VM, Teofilovici F, Yalcin I, Bradley R, Cameron DA. The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 31: TPS1136-TPS1136. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps1136 |
0.557 |
|
| 2013 |
Awada A, Spector N, El-Hariry I, Rodriguez A, Erban J, Cortes J, Gomez H, Kong A, Hickish T, Fein L, Vahdat L, MacPherson I, Canon J, Mansoor S, Giovanne A, et al. Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-16-23 |
0.378 |
|
| 2012 |
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. Journal of the National Cancer Institute. 104: 1625-34. PMID 22962693 DOI: 10.1093/jnci/djs374 |
0.3 |
|
| 2012 |
Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J. Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 629-37. PMID 22410461 DOI: 10.2967/jnumed.111.096685 |
0.328 |
|
| 2012 |
Nafi SM, Kong A, Gijsen M, Kramer-Marek G, Capala J. 415 Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer European Journal of Cancer. 48: 126. DOI: 10.1016/S0959-8049(12)72213-X |
0.663 |
|
| 2012 |
Pistilli B, Urruticoechea A, Chan S, Han H, Jerusalem G, Kong A, Ru Q, Ruquet S, Sternberg D, Saura C. Ph Ib/Ii Study Of BKM120 Plus Trastuzumab (T) in Patients With T-resistant HER2+ Advanced Breast Cancer (BC) Annals of Oncology. 23: ix116. DOI: 10.1016/s0923-7534(20)32887-8 |
0.448 |
|
| 2012 |
Feldinger K, Kerry J, Gijsen M, Murphy G, Kong A. 86P The Role of Adam17 in Her2 Moderately Expressing Breast Cancer Annals of Oncology. 23: ii39. DOI: 10.1016/s0923-7534(19)65750-9 |
0.768 |
|
| 2012 |
Gijsen M, Tang P, Leung W, Roxanis I, Kong A. 24P PTPN9 is a Negative Regulator of HER3 Phosphorylation and a Prognostic Biomarker in HER2 Positive Breast Cancer Annals of Oncology. 23: ii21-ii22. DOI: 10.1016/s0923-7534(19)65669-3 |
0.643 |
|
| 2011 |
Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget. 2: 728-36. PMID 21908901 DOI: 10.18632/oncotarget.313 |
0.438 |
|
| 2011 |
Waterhouse BR, Gijsen M, Tullis I, Barber P, Vojnovic B, Kong A. Abstract 2235: FRET assay to assess EGFR/HER2 dimerization in cancer cell lines Cancer Research. 71: 2235-2235. DOI: 10.1158/1538-7445.Am2011-2235 |
0.42 |
|
| 2010 |
Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. Plos Biology. 8: e1000563. PMID 21203579 DOI: 10.1371/journal.pbio.1000563 |
0.728 |
|
| 2010 |
Gijsen M, King P, Perera T, Parker P, Larijani B, Harris A, Kong A. Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer Breast Cancer Research. 12. DOI: 10.1186/bcr2493 |
0.697 |
|
| 2008 |
Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. Plos One. 3: e2881. PMID 18682844 DOI: 10.1371/journal.pone.0002881 |
0.682 |
|
| 2008 |
Kong A, Calleja V, Leboucher P, Harris A, Parker P, Larijani B. Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells European Journal of Cancer Supplements. 6: 9. DOI: 10.1016/S1359-6349(08)71210-2 |
0.704 |
|
| 2006 |
Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, Parker PJ, Larijani B. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Research. 66: 2834-43. PMID 16510606 DOI: 10.1158/0008-5472.CAN-05-2994 |
0.747 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2021 |
Feeney L, Jain Y, Beasley M, Donnelly O, Kong A, Moleron R, Nallathambi C, Rolles M, Sanghera P, Tin A, Ulahannan D, Walter HS, Webster R, Metcalf R. Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma. Cancers. 13. PMID 34503145 DOI: 10.3390/cancers13174336 |
0.298 |
|
| 2023 |
Ng K, Metcalf R, Sacco J, Kong A, Wheeler G, Forsyth S, Bhat R, Ward J, Ensell L, Lowe H, Spanswick V, Hartley J, White L, Lloyd-Dehler E, Forster M. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK. Bmj Open. 13: e070391. PMID 38011968 DOI: 10.1136/bmjopen-2022-070391 |
0.294 |
|
| 2016 |
Kong A, Rea D, Ahmed S, Beck JT, López RL, Biganzoli L, Armstrong AC, Aglietta M, Alba E, Campone M, Schmitz SH, Lefebvre C, Akimov M, Lee SC. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. Oncotarget. PMID 27129177 DOI: 10.18632/oncotarget.8974 |
0.293 |
|
| 2020 |
Kong A, Good J, Kirkham A, Savage J, Mant R, Llewellyn L, Parish J, Spruce R, Forster M, Schipani S, Harrington K, Sacco J, Murray P, Middleton G, Yap C, et al. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the trial protocol. Bmj Open. 10: e033009. PMID 32184305 DOI: 10.1136/bmjopen-2019-033009 |
0.289 |
|
| 2018 |
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet (London, England). PMID 30449623 DOI: 10.1016/S0140-6736(18)32752-1 |
0.282 |
|
| 2012 |
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. The Cochrane Database of Systematic Reviews. 4: CD003916. PMID 22513918 DOI: 10.1002/14651858.CD003916.pub4 |
0.265 |
|
| 2012 |
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. The Cochrane Database of Systematic Reviews. 3: CD003916. PMID 22419290 DOI: 10.1002/14651858.CD003916.pub3 |
0.265 |
|
| 2024 |
Mehanna H, Gaunt P, Kong A, Hartley A, Sanghera P, Forster M, Sen M, Paleri V, Fong C, Geropantas D, Srinivasan D, Garikipati S, Moleron R, Casswell G, Aynsley E, et al. CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer. Trials. 25: 50. PMID 38221636 DOI: 10.1186/s13063-023-07881-1 |
0.261 |
|
| 2021 |
Ganti A, Kong A, Marchlewicz E, Brannman L. P50.09 Estimates of First-Line Extensive Stage Small Cell Lung Cancer Treatment Rates from a U.S. Claims Database Journal of Thoracic Oncology. 16: S515-S516. DOI: 10.1016/J.JTHO.2021.01.907 |
0.237 |
|
| 2022 |
Azad A, Kong A. The Therapeutic Potential of Imidazole or Quinone-Based Compounds as Radiosensitisers in Combination with Radiotherapy for the Treatment of Head and Neck Squamous Cell Carcinoma. Cancers. 14. PMID 36230623 DOI: 10.3390/cancers14194694 |
0.236 |
|
| 2012 |
Kong A, Rea D, Ahmed S, Beck JT, López López R, Biganzoli L, Armstrong A, Aglietta M, Alba E, Campone M, Akimov M, Matano A, Lefebvre C, Lee S. Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer. Journal of Clinical Oncology. 30: 530-530. DOI: 10.1200/jco.2012.30.15_suppl.530 |
0.233 |
|
| 2018 |
Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, et al. The clinical impact of using complex molecular profiling strategies in routine oncology practice. Oncotarget. 9: 20282-20293. PMID 29755651 DOI: 10.18632/Oncotarget.24757 |
0.225 |
|
| 2018 |
Mehanna H, Kong A, Hartley A, Mistry P, Dalby M, Fulton-Lieuw T, Robinson M, Gray A, Foran B, Sen M, O'Toole L, Dyker K, Al Booz H, Moleron R, Brennan S, et al. Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii729-viii730. PMID 32138008 DOI: 10.1093/annonc/mdy424.046 |
0.208 |
|
| 2021 |
De Felice F, Bird T, Michaelidou A, Jeannon JP, Simo R, Oakley R, Lyons A, Fry A, Cascarini L, Asit A, Thavaraj S, Reis Ferreira M, Petkar I, Kong A, Lei M, et al. Clinical outcomes in relapsed oropharyngeal cancer after definitive (chemo)radiotherapy. Oral Diseases. PMID 34338394 DOI: 10.1111/odi.13985 |
0.204 |
|
| 2017 |
Mehanna HM, Sen M, Chester JD, Sanghera P, Paleri V, Gaunt P, Babrah J, Hartley AGJ, Kong A, Al-Booz H, Foran B, Miles E, Robinson M, Jepson M, Donnovan J, et al. Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE). Journal of Clinical Oncology. 35: TPS6091-TPS6091. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS6091 |
0.184 |
|
| 2024 |
Patel A, Brock K, Slade D, Gaunt C, Kong A, Mehanna H, Billingham L, Gaunt P. Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial. Bmc Medical Research Methodology. 24: 11. PMID 38218799 DOI: 10.1186/s12874-024-02142-4 |
0.184 |
|
| 2018 |
Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, et al. "Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach." Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30307465 DOI: 10.1093/annonc/mdy452 |
0.179 |
|
| 2016 |
Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines. The Journal of Laryngology and Otology. 130: S181-S190. PMID 27841130 DOI: 10.1017/S002221511600061X |
0.174 |
|
| 2019 |
Subramaniam D, Pavilack M, Huo H, Shenolikar R, Kong A, Moynihan M, Marchlewicz E, Larson C. P2.16-37 Impact of Brain Metastases on Healthcare Utilisation and Costs in Patients with NSCLC Treated with EGFR-TKIs Journal of Thoracic Oncology. 14: S880. DOI: 10.1016/j.jtho.2019.08.1904 |
0.163 |
|
| 2021 |
Vasiliadou I, Breik O, Baker H, Leslie I, Sim VR, Hegarty G, Michaelidou A, Nathan K, Hartley A, Good J, Sanghera P, Fong C, Urbano TG, Lei M, Petkar I, ... ... Kong A, et al. Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers. 13. PMID 33808781 DOI: 10.3390/cancers13061413 |
0.156 |
|
| 2021 |
Harrington KJ, Kong A, Mach N, Chesney JA, Castelo B, Rischin D, Cohen EE, Radcliffe H, Gumuscu B, Snyder W, Siu LL. Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232. Journal of Clinical Oncology. 39: 6036-6036. DOI: 10.1200/JCO.2021.39.15_SUPPL.6036 |
0.154 |
|
| 2019 |
Forster MD, Sacco JJ, Kong AH, Wheeler G, Forsyth S, Bhat R, Blair K, Lowe H, Spanswick VJ, Ensell L, Hartley JA, White L. EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer. Journal of Clinical Oncology. 37: TPS6091-TPS6091. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS6091 |
0.152 |
|
| 2020 |
Harrington KJ, Kong A, Mach N, Chesney J, Castelo Fernandez B, Rischin D, Cohen EEW, Radcliffe HS, Gumuscu B, Cheng J, Snyder W, Siu LL. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32669371 DOI: 10.1158/1078-0432.CCR-20-1170 |
0.133 |
|
| 2018 |
Vigneswara V, Kong A. Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29444313 DOI: 10.1093/annonc/mdy065 |
0.132 |
|
| 2012 |
Capala J, Kong A, Kramer-Marek G, Gijsen M. Reply: PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model Journal of Nuclear Medicine. 53: 1655-1656. DOI: 10.2967/jnumed.112.109496 |
0.132 |
|
| 2018 |
Payne K, Spruce R, Beggs A, Sharma N, Kong A, Martin T, Parmar S, Praveen P, Nankivell P, Mehanna H. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head & Neck. PMID 29542214 DOI: 10.1002/hed.25140 |
0.131 |
|
| 2021 |
Bresadola L, Weber D, Ritzel C, Löwer M, Bukur V, Akilli-Öztürk Ö, Becker J, Mehanna H, Schrörs B, Vascotto F, Sahin U, Kong A. Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient. International Journal of Molecular Sciences. 22. PMID 34299215 DOI: 10.3390/ijms22147583 |
0.131 |
|
| 2019 |
Jones D, Mehanna H, Mistry P, Dalby M, Fulton-Lieuw T, Kong A, Dunn J, Gray A. Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC) Annals of Oncology. 30: v450-v451. DOI: 10.1093/annonc/mdz252.003 |
0.13 |
|
| 2021 |
Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, Petschenka J, Diken M, Kreiter S, Türeci Ö, Sahin U, Vascotto F. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16 cancer. Cancer Immunology, Immunotherapy : Cii. PMID 34971406 DOI: 10.1007/s00262-021-03134-9 |
0.126 |
|
| 2024 |
Arshad M, Azad A, Chan PYK, Vigneswara V, Feldinger K, Nafi SNM, Laporte-Maguire E, De Santo C, Zuo J, Shaaban AM, Kong A. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models. British Journal of Cancer. PMID 38600326 DOI: 10.1038/s41416-024-02665-z |
0.12 |
|
| 2019 |
Jones DA, Mistry P, Dalby M, Fulton-Lieuw T, Kong AH, Dunn J, Mehanna HM, Gray AM. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. European Journal of Cancer (Oxford, England : 1990). 124: 178-185. PMID 31794928 DOI: 10.1016/j.ejca.2019.10.025 |
0.107 |
|
| 2019 |
Golusinski P, Di Maio P, Pehlivan B, Colley S, Nankivell P, Kong A, Hartley A, Mehanna H. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncology. 88: 145-152. PMID 30616785 DOI: 10.1016/j.oraloncology.2018.11.020 |
0.105 |
|
| 2022 |
Love SB, Cafferty F, Snowdon C, Carty K, Savage J, Pallmann P, McParland L, Brown L, Masters L, Schiavone F, Hague D, Townsend S, Amos C, South A, Sturgeon K, ... ... Kong A, et al. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials. 23: 757. PMID 36068599 DOI: 10.1186/s13063-022-06680-4 |
0.099 |
|
| 2018 |
Galot R, Licitra LF, Le Tourneau C, Guigay J, Tinhofer I, Kong AH, Caballero CA, Fortpied C, Govaerts A, Staelens D, Raveloarivahy T, Laes J, Canon JR, Henry S, Saada-Bouzid E, et al. EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM". Journal of Clinical Oncology. 36: TPS6095-TPS6095. DOI: 10.1200/JCO.2018.36.15_SUPPL.TPS6095 |
0.098 |
|
| 2020 |
Kong AP. The Impact of COVID-19 on Speakers With Aphasia: What Is Currently Known and Missing? Journal of Speech, Language, and Hearing Research : Jslhr. 1-5. PMID 33306438 DOI: 10.1044/2020_JSLHR-20-00371 |
0.098 |
|
| 2021 |
Galot R, Le Tourneau C, Saada-Bouzid E, Daste A, Even C, Debruyne P, Henry S, Zanetta S, Rutten A, Licitra L, Canon JL, Kaminsky MC, Specenier P, Rottey S, Guigay J, ... Kong A, et al. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. European Journal of Cancer (Oxford, England : 1990). 158: 17-26. PMID 34638090 DOI: 10.1016/j.ejca.2021.09.003 |
0.096 |
|
| 2018 |
Kong AP, Centeno J. Research and clinical services in Chinese aphasia: A recent update. Aphasiology. 32: 115-116. PMID 31534294 DOI: 10.1080/02687038.2018.1486372 |
0.082 |
|
| 2009 |
Kong AP. The use of main concept analysis to measure discourse production in Cantonese-speaking persons with aphasia: a preliminary report. Journal of Communication Disorders. 42: 442-64. PMID 19643430 DOI: 10.1016/j.jcomdis.2009.06.002 |
0.078 |
|
| 2018 |
O'Beirn M, Benghiat H, Meade S, Heyes G, Sawlani V, Kong A, Hartley A, Sanghera P. The Expanding Role of Radiosurgery for Brain Metastases. Medicines (Basel, Switzerland). 5. PMID 30110927 DOI: 10.3390/medicines5030090 |
0.073 |
|
| 2016 |
Mehanna HM, McConkey CC, Hartley AGJ, Fulton-Lieuw MT, Grumett J, Robinson M, Foran B, Sen M, Kong A, Dunn J. De-ESCALaTE: Comparison of early and late toxic events in low-risk HPV positive oropharyngeal carcinoma patients treated with chemoradiotherapy, cetuximab versus cisplatin. Journal of Clinical Oncology. 34: TPS6103-TPS6103. DOI: 10.1200/JCO.2016.34.15_SUPPL.TPS6103 |
0.072 |
|
| 2002 |
Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: Systematic review and meta-analysis Lancet Infectious Diseases. 2: 692-699. PMID 12409050 DOI: 10.1016/S1473-3099(02)00441-3 |
0.07 |
|
| 2018 |
Harrington KJ, Kong AH, Mach N, Rordorf T, Corral Jaime J, Espeli V, Treichel S, Gumuscu B, Kim JJ, Chesney JA. Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232). Journal of Clinical Oncology. 36: 6036-6036. DOI: 10.1200/JCO.2018.36.15_SUPPL.6036 |
0.068 |
|
| 2015 |
Kong APH, Yeh CC. A Taiwanese Mandarin main concept analysis (TM-MCA) for quantification of aphasic oral discourse International Journal of Language and Communication Disorders. 50: 580-592. PMID 25703528 DOI: 10.1111/1460-6984.12157 |
0.065 |
|
| 2017 |
Harrington K, Kong A, Mach N, Rordorf T, Corral J, Espeli V, Treichel S, Cheng J, Kim J, Chesney J. Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) + pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232 Annals of Oncology. 28: v394. DOI: 10.1093/ANNONC/MDX374.061 |
0.06 |
|
| 2021 |
Yazu H, Kong AP, Yoshihata H, Okubo K. Adaptation and validation of the main concept analysis of spoken discourse by native Japanese adults. Clinical Linguistics & Phonetics. 1-17. PMID 33988070 DOI: 10.1080/02699206.2021.1915385 |
0.06 |
|
| 2020 |
Telesca L, Ehren BJ, Hahs-Vaughn DL, Zygouris-Coe VVI, Kong AP. The Effect of Metalinguistic Sentence Combining on Eighth-Grade Students' Understanding and Written Expression of Comparison and Contrast in Science. Journal of Speech, Language, and Hearing Research : Jslhr. 63: 3068-3083. PMID 32757702 DOI: 10.1044/2020_JSLHR-19-00086 |
0.059 |
|
| 2018 |
Kong AP, Wong CW. An Integrative Analysis of Spontaneous Storytelling Discourse in Aphasia: Relationship With Listeners' Rating and Prediction of Severity and Fluency Status of Aphasia. American Journal of Speech-Language Pathology. 1-15. PMID 30458505 DOI: 10.1044/2018_AJSLP-18-0015 |
0.057 |
|
| 2023 |
Brady MC, Ali M, VandenBerg K, Williams LJ, Williams LR, Abo M, Becker F, Bowen A, Brandenburg C, Breitenstein C, Bruehl S, Copland DA, Cranfill TB, Pietro-Bachmann MD, Enderby P, ... ... Kong AP, et al. RELEASE: a protocol for a systematic review based, individual participant data, meta- and network meta-analysis, of complex speech-language therapy interventions for stroke-related aphasia. Aphasiology. 34: 137-157. PMID 37560459 DOI: 10.1080/02687038.2019.1643003 |
0.057 |
|
| 2023 |
Adjogatse D, Michaelidou A, Sanchez Nieto B, Kozarski R, Sassoon I, Evans M, Rackley T, Shah S, Eaton D, Pike L, Curry S, Gould SM, Thomas C, Kong A, Petkar I, et al. Protocol letter: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study (InGReS) - A Phase 1 multicentre feasibility study. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 183: 109645. PMID 36997123 DOI: 10.1016/j.radonc.2023.109645 |
0.055 |
|
| 2016 |
Wallace SJ, Worrall L, Rose T, Le Dorze G, Cruice M, Isaksen J, Kong AP, Simmons-Mackie N, Scarinci N, Gauvreau CA. Which outcomes are most important to people with aphasia and their families? an international nominal group technique study framed within the ICF. Disability and Rehabilitation. 1-16. PMID 27345867 DOI: 10.1080/09638288.2016.1194899 |
0.048 |
|
| 2009 |
Kong AP, Law SP. A linguistic communication measure for monitoring changes in Chinese aphasic narrative production. Clinical Linguistics & Phonetics. 23: 255-69. PMID 19382013 DOI: 10.1080/02699200802673234 |
0.047 |
|
| 2015 |
Kong AP, Lam PH, Ho DW, Lau JK, Humphreys GW, Riddoch J, Weekes B. The Hong Kong version of the Oxford Cognitive Screen (HK-OCS): validation study for Cantonese-speaking chronic stroke survivors. Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition. 1-19. PMID 26702642 DOI: 10.1080/13825585.2015.1127321 |
0.047 |
|
| 2015 |
Pan X, Chen H, Bickerton WL, Lau JK, Kong AP, Rotshtein P, Guo A, Hu J, Humphreys GW. Preliminary findings on the reliability and validity of the Cantonese Birmingham Cognitive Screen in patients with acute ischemic stroke. Neuropsychiatric Disease and Treatment. 11: 2377-90. PMID 26396522 DOI: 10.2147/NDT.S85698 |
0.046 |
|
| 2021 |
Criel Y, Deleu M, De Groote E, Bockstael A, Kong AP, De Letter M. The Dutch Main Concept Analysis: Translation and Establishment of Normative Data. American Journal of Speech-Language Pathology. 1-17. PMID 34100632 DOI: 10.1044/2021_AJSLP-20-00285 |
0.045 |
|
| 2017 |
Lai CC, Law SP, Kong AP. A Quantitative Study of Right Dislocation in Cantonese Spoken Discourse. Language and Speech. 23830916688028. PMID 28139167 DOI: 10.1177/0023830916688028 |
0.044 |
|
| 2020 |
Qin Y, Lee T, Kong APH. Automatic Assessment of Speech Impairment in Cantonese-speaking People with Aphasia. Ieee Journal of Selected Topics in Signal Processing. 14: 331-345. PMID 32499841 DOI: 10.1109/JSTSP.2019.2956371 |
0.04 |
|
| 2017 |
Law SP, Kong AP, Lai C. An analysis of topics and vocabulary in Chinese oral narratives by normal speakers and speakers with fluent aphasia. Clinical Linguistics & Phonetics. 1-12. PMID 28703645 DOI: 10.1080/02699206.2017.1334092 |
0.039 |
|
| 2015 |
Kong AP, Law SP, Wat WK, Lai C. Co-verbal gestures among speakers with aphasia: Influence of aphasia severity, linguistic and semantic skills, and hemiplegia on gesture employment in oral discourse. Journal of Communication Disorders. 56: 88-102. PMID 26186256 DOI: 10.1016/j.jcomdis.2015.06.007 |
0.038 |
|
| 2018 |
Kong AP, Law SP. Cantonese AphasiaBank: An annotated database of spoken discourse and co-verbal gestures by healthy and language-impaired native Cantonese speakers. Behavior Research Methods. PMID 29693232 DOI: 10.3758/s13428-018-1043-6 |
0.038 |
|
| 2014 |
Kong AP. Students' perceptions of using Problem-Based Learning (PBL) in teaching cognitive communicative disorders. Clinical Linguistics & Phonetics. 28: 60-71. PMID 23837406 DOI: 10.3109/02699206.2013.808703 |
0.038 |
|
| 2017 |
Kong AP. The use of free non-dementia-specific Apps on iPad to conduct group communication exercises for individuals with Alzheimer's disease (Innovative Practice). Dementia (London, England). 1471301217727630. PMID 28862041 DOI: 10.1177/1471301217727630 |
0.037 |
|
| 2015 |
Kong AP, Law SP, Kwan CC, Lai C, Lam V. A Coding System with Independent Annotations of Gesture Forms and Functions during Verbal Communication: Development of a Database of Speech and GEsture (DoSaGE). Journal of Nonverbal Behavior. 39: 93-111. PMID 25667563 DOI: 10.1007/s10919-014-0200-6 |
0.037 |
|
| 2021 |
Kong AP. COVID-19 and Aphasia. Current Neurology and Neuroscience Reports. 21: 61. PMID 34674039 DOI: 10.1007/s11910-021-01150-x |
0.036 |
|
| 2016 |
Worrall L, Simmons-Mackie N, Wallace SJ, Rose T, Brady MC, Kong AP, Murray L, Hallowell B. Let's call it "aphasia": Rationales for eliminating the term "dysphasia". International Journal of Stroke : Official Journal of the International Stroke Society. PMID 27384070 DOI: 10.1177/1747493016654487 |
0.036 |
|
| 2019 |
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O’Toole L, Dunn J. OC-011 New insights from the De-ESCALate HPV trial Radiotherapy and Oncology. 132: 10-11. DOI: 10.1016/s0167-8140(19)30177-x |
0.035 |
|
| 2023 |
Kong AP, Lau DK, Lai DH. Measuring pragmatic competence of discourse output among Chinese-speaking individuals with traumatic brain injury. Brain Impairment : a Multidisciplinary Journal of the Australian Society For the Study of Brain Impairment. 24: 660-678. PMID 38167368 DOI: 10.1017/BrImp.2022.36 |
0.034 |
|
| 2013 |
Lee T, Kong AP, Chan VC, Wang H. Analysis of auto-aligned and auto-segmented oral discourse by speakers with aphasia: A preliminary study on the acoustic parameter of duration. Procedia, Social and Behavioral Sciences. 94: 71-72. PMID 24587835 DOI: 10.1016/j.sbspro.2013.09.032 |
0.034 |
|
| 2015 |
Law SP, Kong AP, Lai LW, Lai C. Effects of context and word class on lexical retrieval in Chinese speakers with anomic aphasia. Aphasiology. 29: 81-100. PMID 25505810 DOI: 10.1080/02687038.2014.951598 |
0.031 |
|
| 2011 |
Kong AP. The main concept analysis in cantonese aphasic oral discourse: external validation and monitoring chronic aphasia. Journal of Speech, Language, and Hearing Research : Jslhr. 54: 148-59. PMID 20719865 DOI: 10.1044/1092-4388(2010/09-0240) |
0.031 |
|
| 2012 |
Kong AP, Law SP, Kwan CC, Lam V, Lai C, Lee A. A novel approach to analyze gesture forms and functions in spontaneous oral discourse production of normal speakers. Procedia, Social and Behavioral Sciences. 61: 242-243. PMID 23908678 |
0.029 |
|
| 2019 |
Kong AP, Law SP, Cheung CK. Use of co-verbal gestures during word-finding difficulty among Cantonese speakers with fluent aphasia and unimpaired controls. Aphasiology. 33: 216-233. PMID 30853744 DOI: 10.1080/02687038.2018.1463085 |
0.029 |
|
| 2021 |
Lau DK, Kong AP, Chan MS. Sentence types and complexity of spontaneous discourse productions by Cantonese-speakers with traumatic brain injury- a preliminary report. Clinical Linguistics & Phonetics. 1-17. PMID 34612132 DOI: 10.1080/02699206.2021.1984582 |
0.027 |
|
| 2015 |
Lee T, Lam WK, Kong AP, Law SP. Analysis of Intonation Patterns in Cantonese Aphasia Speech. Oriental Cocosda ... International Conference On Speech Database and Assessments : [Proceedings]. International Conference On Speech Database and Assessments. 2015: 86-89. PMID 28361009 DOI: 10.1109/ICSDA.2015.7357870 |
0.026 |
|
| 2011 |
Kong AP, Weekes BS. Use of the BAT with a Cantonese-Putonghua speaker with aphasia. Clinical Linguistics & Phonetics. 25: 540-52. PMID 21631312 DOI: 10.3109/02699206.2011.570851 |
0.025 |
|
| 2014 |
Kong AP, Abutalebi J, Lam KS, Weekes B. Executive and language control in the multilingual brain. Behavioural Neurology. 2014: 527951. PMID 24868121 DOI: 10.1155/2014/527951 |
0.023 |
|
| 2017 |
Kong AP, Law SP, Chak GW. A Comparison of Coverbal Gesture Use in Oral Discourse Among Speakers With Fluent and Nonfluent Aphasia. Journal of Speech, Language, and Hearing Research : Jslhr. 1-16. PMID 28609510 DOI: 10.1044/2017_JSLHR-L-16-0093 |
0.022 |
|
| 2015 |
Kong AP, Whiteside J, Bargmann P. The Main Concept Analysis: Validation and sensitivity in differentiating discourse produced by unimpaired English speakers from individuals with aphasia and dementia of Alzheimer type. Logopedics, Phoniatrics, Vocology. 1-13. PMID 26059177 DOI: 10.3109/14015439.2015.1041551 |
0.021 |
|
| 2023 |
Kong AP, Cheung RTH, Wong GHY, Choy JCP, Dai R, Spector A. Spoken discourse in episodic autobiographical and verbal short-term memory in Chinese people with dementia: the roles of global coherence and informativeness. Frontiers in Psychology. 14: 1124477. PMID 38022958 DOI: 10.3389/fpsyg.2023.1124477 |
0.021 |
|
| 2019 |
Kong AP, Lau DK, Cheng CY. Analysing coherence of oral discourse among Cantonese speakers in Mainland China with traumatic brain injury and cerebrovascular accident. International Journal of Speech-Language Pathology. 1-11. PMID 30897971 DOI: 10.1080/17549507.2019.1581256 |
0.02 |
|
| 2010 |
Kong AP, Law SP, Lee AS. An investigation of use of non-verbal behaviors among individuals with aphasia in Hong Kong: Preliminary data. Procedia, Social and Behavioral Sciences. 6: 57-58. PMID 23908676 |
0.02 |
|
| 2012 |
Lee A, Kong AP, Law SP. Using forced alignment for automatic acoustic-phonetic segmentation of aphasic discourse. Procedia, Social and Behavioral Sciences. 61: 92-93. PMID 23908677 |
0.016 |
|
| 2017 |
Ho DW, Kong AP, Koon NT. Verbal short-term memory and language impairments in Cantonese speakers after stroke. International Journal of Speech-Language Pathology. 1-10. PMID 28425814 DOI: 10.1080/17549507.2017.1287218 |
0.013 |
|
| 2011 |
Kong AP. Family members' report on speech-language pathology and community services for persons with aphasia in Hong Kong. Disability and Rehabilitation. 33: 2633-45. PMID 22082073 DOI: 10.3109/09638288.2011.579220 |
0.012 |
|
| 2021 |
Kong AP, Chan KP, Jagoe C. Systematic Review of Training Communication Partners of Chinese-speaking Persons With Aphasia. Archives of Rehabilitation Research and Clinical Translation. 3: 100152. PMID 34977535 DOI: 10.1016/j.arrct.2021.100152 |
0.01 |
|
| 2017 |
Kong AP, Linnik A, Law SP, Shum WW. Measuring discourse coherence in anomic aphasia using Rhetorical Structure Theory. International Journal of Speech-Language Pathology. 1-16. PMID 28306394 DOI: 10.1080/17549507.2017.1293158 |
0.01 |
|
| 2013 |
Kong AP, Law SP, Wat W, Lai C. Employment of gestures in spontaneous verbal discourse by speakers with aphasia. Procedia, Social and Behavioral Sciences. 94. PMID 24400023 DOI: 10.1016/j.sbspro.2013.09.098 |
0.01 |
|
| Hide low-probability matches. |